Global Hypozincemia Drugs Market, By Type (Type 1 or Acrodermatitis Enteropathica and Type II Hypozincemia), Treatment (Zinc Supplements, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Hypozincemia Drugs Market Analysis and Size
The hypozincemia drugs market is expected to witness significant growth during the forecast period. The factors fuel the growth for the hypozincemia drugs market are the adoption of reduced dietary intake, insufficient absorption, increased loss and increased use of the body system. However, the increased occurrence of heart, renal, liver disease and type 2 diabetes worldwide will raise the global demand for hypozincemia drugs. The symptoms include unexplained weight loss, wounds that won't heal, lack of alertness, and decreased sense of smell and taste.
Data Bridge Market Research analyses a growth rate in the hypozincemia drugs market in the forecast period 2023-2030. The expected CAGR of hypozincemia drugs market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 500 million in 2022, and it would grow upto USD 738.73 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hypozincemia Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Type 1 or Acrodermatitis Enteropathica and Type II Hypozincemia), Treatment (Zinc Supplements, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), Metagenics, Inc., Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Twinlab Consolidated Corporation (U.S.), Amway Corp.(U.S.), DSM (Netherlands)
|
|
Market Opportunities
|
|
Market Definition
Zinc is a mineral that is present in the body and is responsible for body functions. Its deficiency is difficult to diagnose hypozincemia, or the deficiency of zinc vitamin, is mainly caused by unbalanced dietary intake. Low proportion of zinc in the body leads to major genetic disorders, male fertility issues, premature growth and slow sexual maturity in children.
Hypozincemia Drugs Market Dynamics
Drivers
- Increasing Rapid Lifestyle Changes and Improper Diet
With the fast pacing life, more and more people are indulging in improper diets having nutrient deficit foods that somewhat lead to zinc deficiency. Improper lifestyle leads to various diseases that impacts the market growth.
Opportunities
- Rising Awareness For Disease Treatment
Growing awareness among patients and several healthcare professionals for the treatment of different types of deficiency syndromes and more usage of various supplements are the major factors that are expected to boost the demand for market during the forecast period of 2023-2030.
- Increasing Prevalence of Diabetes
The number of people suffering from diabetes elevated from 108 million in 1980 to 422 million in 2014. Incidence has risen more rapidly in low and middle-income countries compared to high-income countries. Between 2000 and 2019, there was a 3% increase in diabetes mortality rates by age. In 2019, diabetes and kidney disease because of diabetes caused an estimated 2 million deaths. Several studies have shown that zinc improves glucose levels in people suffering from diabetes. This leads to the market growth.
Restraints/Challenges
- Lack of Awareness
The lack of awareness about these disorders and the unavailability of numerous awareness programs hamper the market growth. The available drugs have not shown disease-modifying activity and are still primarily inadequate for managing major unmet needs.
This hypozincemia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypozincemia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hypozincemia Drugs Market Scope
The hypozincemia drugs market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Type 1 or Acrodermatitis Enteropathica
- Type II Hypozincemia
Treatment
- Zinc Supplements
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hypozincemia Drugs Market Regional Analysis/Insights
The hypozincemia drugs market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the hypozincemia drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for hypozincemia drugs market due to lack of knowledge of dietary supplements and a sufficient amount of zinc involved in the diet.
North America dominates the market due to the presence of the products primary manufacturers, high spending on research and development and health care and qualified professionals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hypozincemia Drugs Market Share Analysis
The hypozincemia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hypozincemia drugs market.
Key players operating in the hypozincemia drugs market include:
- Pfizer Inc (U.S.)
- Metagenics, Inc.(U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Twinlab Consolidated Corporation (U.S.)
- Amway Corp.(U.S.)
- DSM (Netherlands)
SKU-